Deroma, a Njord Partners Portfolio Company, Appoints New CEO
27.3.2024 11:00:00 EET | Business Wire | Press release
Deroma, the world’s largest Terracotta producer, together with Njord Partners, today announce the appointment of Stefano Mele as CEO of Deroma, effective from 4 March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327185499/en/
Stefano is a highly experienced business leader in Italy, focused on the manufacturing and industrial sectors where he has a track record of delivering successful growth strategies. Stefano’s diverse background spans various sectors, from textiles and ceramics to machines and printing. As a proven leader, he has held key roles as CEO and Managing Director in international companies and business units.
Stefano has most recently been CEO of Ceramica Dolomite, an Italian bathroom sanitaryware manufacturer specialized in ceramics with 360 employees. In less than two years, he has transformed the company, which was earmarked for closure, by relaunching the commercial production of the company, creating 7 new product series in one year and developing collaboration with other sanitaryware manufacturers to facilitate reshoring their production. Before this, Stefano was CEO of Fabbri Group, an Italian fresh food packaging designer and producer.
Stefano’s multi-lingual skills and extensive international experience spanning Europe, North and South America, India and China will be invaluable for Deroma’s global expansion.
Stefano Mele, incoming CEO, commented: “I am excited to join Deroma as CEO. I hope to use my proven leadership skills and industry expertise to drive the next phase of Deroma’s growth, working together with the whole Deroma team to produce outstanding products based on the legacy of craftmanship developed over almost 70 years. I look forward to working closely with Njord Partners to deliver on this incredible opportunity.”
Arvid Trolle, Partner at Njord Partners, said: “Stefano is a world-class leader and he will be instrumental in our exciting plans to double the size of the business and further expand globally. Stefano’s experience across the wider ceramics industry will enable Deroma to fuel the gardening passion of millions of people with the continued pursuit of the highest quality Terracotta, plastic and glazed pots.”
About Stefano Mele
Stefano began his career in 1990 as a Project Engineer at Alcatel. He went on to hold management positions at Nuova Fima, Viappiani Printong, SIAT and GEA Group. Most recently, he was CEO of Fabbri Group (2019-2022) where he achieved double-digit increases in both turnover and EBITDA through entering new markets and launching a new range of environmentally sustainable products and integrated software solutions. Since 2022, Stefano has been the CEO of Ceramica Dolomite where he has relaunched their commercial production, creating seven new product series in less than two years.
About Deroma
Deroma Group is the largest Terracotta producer globally and is headquartered in Italy. Deroma produces in Europe and the United States and operates globally, with recent expansion in the UK, Asia Pacific and Eastern Europe. As a global leader in high-end garden products, Deroma also designs and distributes pots and vases made of plastic, glazed and other materials. Deroma was successfully acquired by Njord Partners in June 2021.
To find out more visit: https://deroma.com
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations. Its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value, with a particular focus on existing debt securities and structures.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327185499/en/
Contact information
Media enquiries:
via Camarco
njord@apcoworldwide.com
Jennifer Renwick +44 7928 471 013
Letaba Rimell +44 7715 530 664
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom